Sunday, August 16, 2015 8:25:00 PM
It's a 120pt Phase II trial, just two clinical sites. That is enough to provide data supporting a larger scale Phase III trial upon which NDA filing would be based. But I am not aware--in the neuro sector--of such a small Phase II ever having been sufficient for approval. Maybe in oncology...
There are some programs that are using their first actual efficacy trials as their pivotal trials for NDA submission: The huge Alzheimer's trials of monoclonal antibodies and BACE inhibitors, and maybe more to the point, Biogen/Isis Pharma's trial in spinal muscular atrophy. The latter is a relatively small trial, but it is in a rare, devastating genetic disorder.
Sleep apnea is not a small population, and is does not fall under the usual definitions of 'life-threatening'...even though it is deleterious to health; and there is effective treatment available, even if highly flawed and problematic (CPAP). I see no way that the FDA would even accept the filing of an NDA based on this Phase II.
Prospects for Cortex? They depend upon whether Arnold Lippa is able to obtain enough funding to run the trials he needs to run--or at least, to stay functional until the dronabinol trial finishes and hopefully shows positive results....
NP
Recent RSPI News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 01:03:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 01:30:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 01:45:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 01:45:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/17/2023 09:06:03 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/14/2023 09:05:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/12/2023 01:00:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2023 12:45:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 08:05:55 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2023 08:15:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2023 12:52:24 PM
ILUS Provides an Update on the Binding Term Sheet Signed with Actelis Networks (NASDAQ: ASNS) • ILUS • May 31, 2024 12:52 PM
Element79 Gold To Provide Summary and Update on Active Exploration Program, Community Relations at RMEC on June 4 • ELEM • May 30, 2024 1:18 PM
Branded Legacy Secures Exclusive Extraction Partnership with One of the World's Largest Kava Distributors and Producers • BLEG • May 30, 2024 8:30 AM
ECGI Holdings, Inc. Announces $2 Million Debt-to-Equity Conversion • ECGI • May 30, 2024 8:30 AM
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM
One World Products, Inc. Issues Shareholder Update • OWPC • May 29, 2024 8:20 AM